0000899243-15-005097.txt : 20150921 0000899243-15-005097.hdr.sgml : 20150921 20150921170030 ACCESSION NUMBER: 0000899243-15-005097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150918 FILED AS OF DATE: 20150921 DATE AS OF CHANGE: 20150921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRISTOW MICHAEL R CENTRAL INDEX KEY: 0001266125 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 151117868 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-09-18 0 0000907654 ARCA biopharma, Inc. ABIO 0001266125 BRISTOW MICHAEL R ARCA BIOPHARMA, INC. 11080 CIRCLEPOINT ROAD, SUITE 140 WESTMINSTER CO 80020 1 1 0 0 See Remarks Common Stock 2015-09-18 4 S 0 1809 6.33 D 46086 D Common Stock 19986 I By Investocor Trust as sole Trustee Common Stock 25459 I By NFS Custodian for Michael Bristow's IRA Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan"). Includes (i) remaining 5,952 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) 6,075 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning on 2/27/16, and (iii) 6,871 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 27,188 previously reported shares of common stock held directly. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $6.33 to $6.35. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. Includes 118 shares that were inadvertently omitted from the prior filing. President and Chief Executive Officer /s/ Brian L. Selby, Attorney-in-Fact 2015-09-21